Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Rating) saw a large drop in short interest in April. As of April 30th, there was short interest totalling 136,000 shares, a drop of 92.4% from the April 15th total of 1,800,000 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 3,500,000 shares, the days-to-cover ratio is currently 0.0 days.

Shares of Lixte Biotechnology stock traded up $0.06 during trading hours on Friday, reaching $0.98. 553 shares of the stock traded hands, compared to its average volume of 2,181,802. The company has a 50 day moving average price of $1.29 and a 200 day moving average price of $1.54. Lixte Biotechnology has a one year low of $0.91 and a one year high of $4.95.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Lixte Biotechnology by 191.9% in the 3rd quarter. BlackRock Inc. now owns 13,425 shares of the company’s stock valued at $28,000 after acquiring an additional 8,826 shares during the last quarter. Morgan Stanley purchased a new position in shares of Lixte Biotechnology in the first quarter worth about $69,000. Finally, Geode Capital Management LLC acquired a new stake in Lixte Biotechnology during the third quarter worth about $78,000. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

About Lixte Biotechnology (Get Rating)

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.

Read More

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with's FREE daily email newsletter.